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The Raf/MEK/extracellular signal–regulated kinase (ERK) signaling pathway regulates diverse cellular pro-
cesses such as proliferation, differentiation, and apoptosis and is implicated as an important contributor to 
the pathogenesis of cardiac hypertrophy and heart failure. To examine the in vivo role of Raf-1 in the heart, we 
generated cardiac muscle–specific Raf-1–knockout (Raf CKO) mice with Cre-loxP–mediated recombination. 
The mice demonstrated left ventricular systolic dysfunction and heart dilatation without cardiac hypertrophy 
or lethality. The Raf CKO mice showed a significant increase in the number of apoptotic cardiomyocytes. The 
expression level and activation of MEK1/2 or ERK showed no difference, but the kinase activity of apoptosis 
signal–regulating kinase 1 (ASK1), JNK, or p38 increased significantly compared with that in controls. The 
ablation of ASK1 rescued heart dysfunction and dilatation as well as cardiac fibrosis. These results indicate 
that Raf-1 promotes cardiomyocyte survival through a MEK/ERK–independent mechanism.
Introduction
Heart failure, one of the leading causes of both morbidity and mor-
tality in developed countries, is the convergent phenotype of vari-
ous diseases that cause loss and dysfunction of cardiomyocytes. 
Series of parallel and convergent signaling pathways are activated 
that lead to the common phenotype of heart failure, but molecu-
lar mechanisms underlying the pathogenesis of heart failure await 
clarification. Recent studies have indicated that apoptosis may be 
an important feature of heart failure (1).
Raf is a family of 3 serine/threonine–specific kinases (A-Raf, 
B-Raf, and Raf-1) ubiquitously expressed throughout embryonic 
development. The principal function of the Raf protein kinases 
appears to be participation in the highly conserved Ras/Raf/MEK/
extracellular signal–regulated kinase (ERK) intracellular signaling 
pathway, which has been implicated in the transduction of signals 
directing cell proliferation and differentiation. In addition, Raf-1 
activation of the MEK/ERK pathway has been associated with 
inhibition of apoptosis, leading to cell survival (2, 3).
To determine the in vivo role of Raf-1, Raf-1 knockout mice were 
generated (4, 5). The embryos of these mice are growth retarded 
and die progressively around midgestation with defects in the pla-
centa and in the liver due to apoptosis (4). The phenotype observed 
appears to be the result of a lack of activation of Raf-1–specific effec-
tors distinct from the ERK pathway (4–6). At present, the molecular 
mechanisms underlying the MEK/ERK–independent prosurvival 
function of Raf-1 are poorly understood. A recent study has demon-
strated that Raf-1 physically interacts with the proapoptotic, stress-
activated mitogen-activated protein kinase kinase kinase, apoptosis 
signal–regulating kinase 1 (ASK1) (7), which is a key element in the 
mechanism of stress- and cytokine-induced apoptosis (8, 9). A vari-
ety of stress-related stimuli activate ASK1, including TNF-α, reactive 
oxygen species, and Fas. ASK1 phosphorylates and activates mito-
gen-activated protein kinase kinase 4/7 (MKK4/7) and MKK3/6, 
which in turn activate JNK and p38 MAPK, respectively.
In the heart, the MEK/ERK pathway has been implicated as 
the signaling cascade leading to hypertrophy of cardiomyocytes 
(10–12), although a number of additional studies have disput-
ed the importance of the pathway in the regulation of cardiac 
hypertrophy (13–15). A recent study of MEK1 transgenic mice 
has suggested that the MEK/ERK signaling pathway stimulates 
a hypertrophic response associated with resistance to apoptosis 
(16). However, the in vivo role of Raf-1 in the heart has not been 
identified yet. In this study, we generated cardiac-specific Raf-1 
knockout (Raf CKO) mice to clarify the role of Raf-1 in the heart. 
These mice showed left ventricular (LV) dysfunction and heart 
dilatation with an increased number of apoptotic cells. These phe-
notypes were rescued by inactivation of ASK1. To the best of our 
knowledge, this is the first study demonstrating that Raf-1 plays a 
role at the organ level.
Results
Generation of cardiac muscle–specific Raf-1 knockout mice. To obtain a 
cardiac muscle–specific knockout of the c-raf-1 gene, we used Cre-
Nonstandard abbreviations used: ASK1, apoptosis signal–regulating kinase 1; CTL, 
control littermate of c-raf-1flox/flox:α-MHCCre(–) mice; ERK, extracellular signal–regu-
lated kinase; FS, fractional shortening; LV, left ventricle/ventricular; α-MHCCre, 
transgenic mice expressing Cre recombinase under the control of the α-myosin heavy 
chain promoter; MKK, mitogen-activated protein kinase kinase; Raf CKO, cardiac 
muscle–specific Raf-1 knockout; RV, right ventricle.
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loxP strategies, which employ c-raf-1 floxed-allele mice (6) and trans-
genic mice expressing the Cre recombinase under the control of 
the α-myosin heavy chain promoter (α-MHCCre mice) (17). This 
floxed c-raf-1 allele contains 2 loxP sites, which have been inserted 
at 3′ and 5′ of exon 3 of the c-raf-1 gene (designated “c-raf-1flox”). Mice 
homozygous to the c-raf-1flox allele mice appeared to be phenotypi-
cally indistinguishable from wild-type animals, and the protein lev-
els of Raf-1 were similar to those in wild-type mice (6). To achieve 
conditional inactivation of the c-raf-1 gene in cardiac muscle, 
c-raf-1flox/flox mice were crossed with α-MHCCre mice. To demon-
strate tissue-specific deficiency of Raf-1, we used Western blot 
analysis to examine the protein levels of Raf-1 in various tissues 
extracted from c-raf-1flox/flox:α-MHCCre(+) mice, which harbor Raf 
CKO. Immunoblotting indicated a marked reduction in the Raf-1 
protein exclusively in the heart of Raf CKO mice with no detectable 
reductions in other tissues such as liver, spleen, and kidney (Figure 
1A). In addition, there was almost no difference in cardiac Raf-1 
levels between wild-type and c-raf-1flox/flox:α-MHCCre(–) mice, so the 
latter were used as controls (data not shown).
Conditional depletion of Raf-1 developed heart dysfunction. Expected 
mendelian ratios of c-raf-1flox/flox:α-MHCCre(–) and c-raf-1flox/flox: 
α-MHCCre(+) (n = 121 and 114, respectively) were detected between 
the offspring of c-raf-1flox/flox:α-MHCCre(–) and c-raf-1flox/flox:α-MHC-
Cre(+), indicating no significant embryonic lethality. The Raf CKO 
mice were born normally and were externally indistinguishable from 
control littermates of c-raf-1flox/flox:α-MHCCre(–) mice (CTLs). The 
mice developed to adulthood, were fertile, and exhibited a normal 
lifespan up to 12 months of age. Thus, the c-raf-1 gene is not essen-
tial for mouse heart development.
To investigate whether the cardiac-specific knockout of Raf-1 
would affect in vivo cardiac function, cardiac performance was 
analyzed by means of echocardiography at 10 weeks of age (Table 
1; Figure 1B). Cardiac contractility was significantly depressed in 
Raf CKO mice compared with that in CTLs as assessed by frac-
tional shortening (FS). The LV end-diastolic and end-systolic 
diameters significantly increased in Raf CKO mice compared with 
CTLs. Although there were no significant differences in septal wall 
thickness between Raf CKO mice and CTLs, posterior wall thick-
ness significantly decreased in Raf CKO mice. Catheterization of 
the LV showed a marked reduction in the maximum or minimum 
first derivative of LV pressure in Raf CKO mice, thus demonstrat-
ing a reduction in myocardial contractility and relaxation (Table 
2). There were no significant differences in heart rate, systolic and 
diastolic pressure, or LV end-diastolic pressure. The mice were fol-
lowed up at 5, 10, and 15 weeks of age (Figure 1C). In Raf CKO 
mice, FS was significantly decreased at 10 weeks compared with 
that at 5 weeks but remained unchanged thereafter.
The Raf CKO mice developed enlarged hearts (Figure 2A) but dis-
played no differences in heart weight or the average ratio of heart 
weight to tibia length or to body weight (Table 2). In addition, 
there were no significant differences in the weight of the LV, RV, 
atrium, lung, or liver. Histological examination of the heart dem-
onstrated LV enlargement in Raf CKO hearts (Figure 2B), while 
also demonstrating that the cross-sectional area of cardiomyocytes 
exhibited no significant differences between Raf CKO mice and 
CTLs (174.2 ± 6.8 μm2 for Raf CKO mice and 184.6 ± 7.7 μm2 for 
CTLs) (Figure 2C). These findings are consistent with LV pump 
dysfunction without ventricular pump failure. In addition, either 
endogenous Raf-1 does not play a role in the regulation of develop-
mental cardiomyocyte hypertrophic growth, or its function in the 
growth process is offset by that of other MEK activators. Masson 
trichrome staining revealed significant fibrosis in intermuscular 
areas in Raf CKO mice compared with those in CTLs (Figure 2D).
Increased apoptosis in hearts with Raf-1 conditional depletion. Raf-1 
activation of the MEK/ERK pathway is associated with inhibition 
of apoptosis, leading to cell survival (2, 3, 18). Therefore, it can be 
hypothesized that the cardiac dysfunction observed in Raf CKO 
mice was associated with an increase in myocyte apoptosis. TUNEL 
assay revealed a significant increase in apoptotic cells in Raf CKO 
hearts at 3, 4, and 5 weeks of age but did not at 2 weeks and after 6 
weeks of age (Figure 3A). The appearance of apoptosis was further 
confirmed by morphological examination, which demonstrated 
condensed chromatin and fragmented nuclei in TUNEL-positive 
cells; these are characteristics of apoptosis. The TUNEL-positive 
cells were identified as cardiac myocytes by anti–α-sarcomeric 
actin staining (Figure 3B).
Analysis of apoptosis-related proteins showed an increased level 
of Bax in Raf CKO mice compared with CTLs. No significant dif-
ference was observed in the level of Bcl-2 (Figure 3C). The ratio of 
Figure 1
Characterization of Raf CKO mice. (A) The expression level of Raf-1 
in indicated tissues was examined with the anti–Raf-1 antibody. Tissue 
homogenates were extracted from CTLs and Raf CKO mice. (B) Trans-
thoracic M-mode echocardiographic tracings in a Raf CKO mouse 
(left) and a CTL (right) at 10 weeks of age. (C) Changes in fractional 
shortening (FS) at 5, 10, and 15 weeks in Raf CKO mice (open circles) 
and CTLs (filled circles). *P < 0.05 versus controls at the same age. 
†P < 0.05 versus Raf CKO at 5 weeks.
Table 1
Echocardiographic measurements of the knockout mice at 10 
weeks of age
 Raf CKO (n = 12) CTLs (n = 12)
LVDd (mm) 4.79 ± 0.14A 4.16 ± 0.08
LVDs (mm) 3.89 ± 0.16A 2.57 ± 0.08
FS (%) 19.3 ± 1.4A 38.4 ± 1.0
IVSd (mm) 0.76 ± 0.04 0.82 ± 0.04
LVPWd (mm) 0.49 ± 0.02A 0.58 ± 0.04
Heart rate (beats/min) 473 ± 16 491 ± 15
LVDd, diastolic left ventricle internal dimension; LVDs, systolic left ven-
tricle internal dimension; IVSd, diastolic interventricle septal wall thick-
ness; LVPWd, diastolic left ventricle posterior wall thickness. Data are 
expressed as mean ± SEM. AP < 0.05 versus CTLs.
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Bcl-2 protein to Bax protein determines survival or death after an 
apoptotic stimulus (19). The Bax/Bcl-2 ratio in Raf CKO mice was 
significantly larger than that in CTLs (Figure 3C).
MAPK activation in hearts with Raf-1 depletion. To test the activation 
profile of MEK1/2 or ERK in Raf CKO hearts, the protein level of 
phosphorylated MEK1/2 or ERK was measured after 3 minutes of 
intra-arterial infusion of endothelin-1 (Figure 4A). A similar level 
of MEK1/2 or ERK phosphorylation was observed in Raf CKO and 
CTL hearts in response to endothelin-1. This indicates that the 
MEK/ERK pathway was not impaired in Raf CKO hearts. To exam-
ine whether the MEK/ERK pathway is involved in cardiac dysfunc-
tion observed in Raf CKO mice, we assessed activation of MEK1/2 
or ERK in the hearts. There were no differences in the basal pro-
tein levels of ERK or MEK1/2 in Raf CKO and CTL hearts, nor in 
the level of phosphorylated ERK or MEK1/2 (Figure 4, B and C). 
The phosphorylation level of p38 significantly increased at 3 weeks 
of age (Figure 4C). The phosphorylation level of JNK at 3 and 4 
weeks of age was significantly enhanced (2.49 ± 0.59–fold increase 
at 4 weeks) in Raf CKO mice compared with that in CTLs (Figure 
4C). We observed no differences in Akt activation in Raf CKO mice 
compared with that in CTLs. This implies that Raf-1 activity is not 
required for ERK activation, presumably because other Raf isoforms 
or MEK activators compensate for the loss of Raf-1. Raf-1 appears 
to promote cell survival in the heart through a MEK/ERK–indepen-
dent mechanism. In addition, these results imply a role of JNK or 
p38, but not ERK, in cardiac dysfunction in Raf CKO mice.
ASK1 ablation rescues abnormalities in mice with Raf-1 conditional 
depletion. A recent in vitro study suggests that Raf-1 promotes 
cell survival by antagonizing ASK1 (7). The ASK1/JNK signaling 
pathway has been reported to be a crucial element of neuronal or 
cardiac apoptosis (20, 21). We first used the immunoprecipitation 
kinase assay to compare the activity of the endogenous ASK1 
proteins in Raf CKO and CTL hearts. The in vitro kinase assay 
clearly showed an increase in the kinase activity of ASK1 in Raf 
CKO hearts compared with controls at 4 weeks of age (Figure 5), 
but no significant difference at 2 or 10 weeks of age. To deter-
mine whether the ASK1 activation in Raf CKO hearts results in 
cardiac dysfunction and dilatation, we generated the Raf-1/ASK1 
double-knockout [c-raf-1flox/flox:α-MHCCre(+):ASK–/–] line by mat-
ing Raf CKO with conventional ASK1 knockout mice. As we previ-
ously reported, ASK1 knockout mice were born at the expected 
mendelian frequency, were indistinguishable in appearance from 
wild-type littermates (9), and displayed no differences in either 
physiological parameters or cardiac performance as analyzed by 
means of echocardiography and hemodynamic measurement (21). 
The Raf-1/ASK1 double-knockout mice were born normally and 
were fertile. The increase in heart size appeared to be reduced in 
double-knockout mice compared with that in c-raf-1flox/flox:α-MHC-
Cre(+):ASK+/+ mice (Raf CKO:ASK+/+) (Figure 6A). The protein level 
of Raf-1 in the double-knockout mice was significantly reduced, 
as in Raf CKO:ASK+/+ mice (Figure 6B). LV end-diastolic diameter 
was significantly reduced and FS increased in the Raf-1/ASK1 
double-knockout mice compared with Raf CKO:ASK+/+ mice (Fig-
Table 2
Physiological base-line parameters of Raf CKO mice at 10 weeks 
of age
 Raf CKO (n = 9) CTLs (n = 7)
Body weight (g) 27.1 ± 1.0 28.8 ± 1.2
Heart weight (mg) 130 ± 4 132 ± 7
LV weight (mg) 89.4 ± 3.6 89.6 ± 4.2
RV weight (mg) 24.1 ± 1.5 26.1 ± 1.6
Atrium weight (mg) 12.6 ± 0.6 13.2 ± 1.2
Lung weight (mg) 141 ± 1 149 ± 5
Tibia length (mm) 17.7 ± 0.2 17.9 ± 0.1
Heart rate (beats/min) 391 ± 33 427 ± 24
Systolic blood pressure (mmHg) 84.6 ± 4.2 86.8 ± 5.1
LV systolic pressure (mmHg) 82.4 ± 2.6 86.0 ± 4.1
LVEDP (mmHg) 1.3 ± 0.3 1.1 ± 0.4
LV dp/dt max (mmHg/s) 6,733 ± 411A 9,657 ± 835
LV dp/dt min (mmHg/s) –4,344 ± 287A –5,957 ± 796
LVEDP, left ventricular end-diastolic pressure. LV dp/dt max and LV dp/dt 
min are the maximum rates of pressure development during contraction 
and relaxation, respectively. Data are expressed as mean ± SEM.  
AP < 0.05 versus CTLs.
Figure 2
Cardiac histological analysis of Raf CKO mice. (A) Photographs of hearts 
removed from CTLs (right) and Raf CKO (left) mice at 10 weeks of age. 
(B) Macroscopic H&E-stained histological section of hearts from CTLs 
(right) and Raf CKO (left) mice at 10 weeks of age. (C) Microscopic H&E-
stained sections of hearts from CTLs (right) and Raf CKO (left) mice. 
(D) Microscopic Masson trichrome–stained section of hearts from CTLs 
(right) and Raf CKO (left) mice. Scale bar: 2 mm (B), 100 μm (C and D).
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ure 6, C and D). The value of LV end-diastolic diameter or FS in 
Raf-1/ASK1 double-knockout mice was similar to that in CTLs:
ASK+/+ and CTL:ASK–/– mice. The double knockout rescued the 
pathology in Raf CKO hearts (Figure 6E). The double-knockout 
hearts exhibited less fibrosis compared with Raf CKO:ASK+/+. The 
phosphorylation levels of JNK and p38 were reduced in the Raf-1/ 
ASK1 double-knockout mice compared with Raf CKO/ASK+/+ 
littermates (Figure 6F). The number of TUNEL-positive cardio-
myocytes significantly decreased in the double-knockout mice at 4 
weeks of age, but not 10 weeks (Figure 6G). Thus, ablation of ASK1 
in cardiomyocytes rescued functional, structural, and histological 
abnormalities observed in Raf CKO mice. This indicates that ASK1 
activation in Raf CKO hearts might be involved in the pathogen-
esis of cardiac dysfunction.
Discussion
In order to better understand the function of Raf-1 in mature car-
diac muscle, we used the Cre-loxP system to specifically inactivate 
the c-raf-1 gene in cardiac muscle. Our data indicate that the c-raf-1 
gene is not essential for mouse heart development or the regula-
tion of developmental cardiomyocyte hypertrophic growth. Our 
data, however, do not exclude the role of the MEK/ERK pathway in 
cardiac development or hypertrophy, since MEK1/2 and ERK can 
be activated in Raf CKO hearts.
Raf CKO mice exhibited cardiac dysfunction and heart dilatation 
at 5 weeks of age. Raf CKO hearts demonstrated a heightened level 
of apoptosis at 3, 4, and 5 weeks but not at 2 weeks and after 6 weeks 
of age, even though cardiac contractility progressively decreased 
during the 10 weeks. These findings suggest that apoptosis is one 
of the early causes of cardiac dysfunction rather than a terminal 
event associated with the end stage. Mice are undergoing marked 
postnatal growth and hypertrophic stimulation during the first 
month after birth. We assume that such stress might transiently 
activate stress-activated signaling molecules such as ASK1 in Raf 
CKO mice and induce cardiomyocyte apoptosis. To ensure that the 
resultant anatomical and functional alterations were not in part 
due to positional effects of the Cre gene, we crossed c-raf-1flox/flox mice 
with mice expressing the Cre recombinase under the control of the 
myosin light chain 2v (MLC2v) promoter (22). We observed similar 
phenotypes in the c-raf-1flox/flox:MLC2v-Cre+/– mice.
Accumulating evidence suggests that apoptosis may be an impor-
tant mode of cell death during heart failure in both humans and 
animal models (1). However, the extent to which apoptosis plays 
a critical role in the pathogenesis of heart failure has remained an 
open question. Our study demonstrates that induction of apopto-
sis leads to the development and progression of cardiac dysfunc-
tion. A number of biochemical studies have indicated a role for 
Raf-1 in apoptosis (2, 3). Recent knockout studies of Raf-1 demon-
strated that c-raf-1–/– mice die in embryogenesis and show vascular 
defects in the yolk sac and placenta as well as increased apoptosis 
in embryonic tissues (4, 5). These findings suggest that Raf-1 plays 
a key role in preventing apoptosis, which is in agreement with the 
findings of our study of the heart. However, it is possible that abla-
tion of Raf-1 affected gene expression of calcium-handling pro-
teins, other ion-handling proteins, and contractile proteins, which 
regulate cardiac contractility. We observed no changes in protein 
expression of calcium-handling proteins such as ryanodine recep-
tor, SERCA, phospholamban, and calsequestrin (data not shown). 
As a limitation of knockout study, we could not exclude the possi-
bility that ablation of one gene leads to alteration of the expression 
profile of unrelated or related genes. In this study, Raf CKO hearts 
did not develop compensatory hypertrophy despite cardiac dys-
function and dilatation, which suggests that Raf-1 is involved in 
compensatory cardiomyocyte growth through a MEK/ERK–inde-
pendent pathway. This could be another important mechanism of 
cardiac dysfunction in Raf CKO mice. Further study will be neces-
sary to elucidate a role of Raf-1 in compensatory hypertrophy in 
response to increased hemodynamic stress.
Raf-1 activation of the MEK/ERK pathway has been associated 
with inhibition of apoptosis (2, 3). However, studies using conven-
tional c-raf-1–/– mice suggest that effectors other than the MEK/ERK 
cascade must mediate the antiapoptotic function of Raf-1 (4, 5). Our 
results indicate that Raf-1 promotes cell survival in the heart, as in 
other tissues, through a MEK/ERK–independent mechanism. In this 
study, we detected a transient increase in ASK1 activity in Raf CKO 
hearts. Furthermore, ablation of ASK1 resulted in the rescue of the 
functional, structural, and histological phenotypes observed in Raf 
CKO mice. These suggested that ASK1 might play an important role 
in the apoptosis-induced abnormalities observed in Raf-1–knockout 
Figure 3
Apoptosis in Raf CKO hearts. (A) Number of TUNEL-positive cells in 
Raf CKO hearts (black bars) at 2, 3, 4, 5, 6, 7, 8, and 10 weeks of 
age compared with CTL hearts (white bars) (n = 3). *P < 0.05 versus 
CTLs at the same age. (B) Confocal analysis of Raf CKO ventricu-
lar myocardium. Triple staining (propidium iodide, TUNEL, and anti– 
α-sarcomeric actin antibody) was performed. Staining for propidium 
iodide and anti–α-sarcomeric actin antibody is shown in red, and that 
for TUNEL in green. In the overlay image, a nucleus stained by both 
TUNEL and propidium iodide is shown in yellow. Scale bar: 20 μm. 
(C) Immunoblot analysis of the apoptosis-related proteins in Raf CKO 
hearts. The expression levels of Bcl-2, Bax, and actin as a control in 
the indicated tissues were examined with their respective antibodies. 
(D) The Bax/Bcl-2 ratio is shown (n = 3).
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hearts. Overexpression of wild-type or constitutively active ASK1 
induces apoptosis in various cells (23), while oxidative stress and 
TNF-induced apoptosis are suppressed in ASK1–/– cells (6, 9). We have 
previously shown that expression of a constitutively active mutant of 
ASK1 in cardiomyocytes results in apoptosis, while isolated ASK–/– 
cardiomyocytes are resistant to H2O2 (21). The ablation of ASK1 in 
mice prevents heart dilatation and cardiac dysfunction following 
pressure overload or myocardial infarction, possibly by inhibiting 
the ASK/JNK signaling pathway (21). The prevention of LV remodel-
ing was accompanied by a reduction in the appearance of apoptotic 
cardiomyocytes in ASK–/– hearts. Thus, the activation of ASK1 in Raf 
CKO mice appears to be a cause of cardiac dysfunction and heart 
dilatation. However, it is still possible that, in mouse hearts in which 
both the ASK1 and the Raf-1 genes have been ablated, the beneficial 
effect of ASK1 ablation on LV remodeling independently cancels the 
detrimental effect of Raf-1 ablation. Alternative pathways aside from 
ASK1, which could contribute to alteration of cell survival, might 
mediate the phenotypes observed in Raf CKO mice. As a candidate, 
we examined Akt activation in Raf CKO mice. We observed no differ-
ence in Akt activation between Raf CKO mice and CTLs.
We detected a transient activation of JNK and 
p38 in Raf CKO mice. We observed no activa-
tion of JNK and p38 in the Raf-1/ASK1 double-
knockout mice. Knockout studies indicate the 
role of the JNK pathway in proapoptotic signal-
ing (24). The ASK1/JNK signaling pathway has 
been reported to be a crucial element of cardiac 
(21) and neuronal apoptosis (20). Thus, we can 
hypothesize that the activation of the ASK1/
JNK signaling pathway might mediate apopto-
sis in Raf CKO hearts. In addition to JNK activa-
tion, it is also possible that p38 activation might 
be involved in the apoptotic pathway.
The molecular target for activated ASK1 to 
induce apoptosis remains to be elucidated. 
It has been reported that overexpression of a 
dominant negative mutant of ASK induced 
cytochrome c release from mitochondria and 
activation of caspase-9 and caspase-3, but not 
of caspase-8, in nonmuscle cells (25). This indi-
cates that mitochondria-initiated activation of 
caspases might be a main mechanism operating 
in the execution of ASK1-induced apoptosis. 
The ratio of Bcl-2 protein to Bax protein deter-
mines survival or death after an apoptotic stimulus (19). In our 
study, we observed a decrease in the ratio of Bcl-2 to Bax in Raf 
CKO hearts, which promotes cell death. However, the mechanism 
underlying this increase in Bax protein level in response to ASK1 
activation in Raf CKO mice remains to be clarified.
It is currently unclear precisely how the Raf-1 protein regulates 
ASK1 activation and whether ASK1 activation is a direct or an indi-
rect consequence of Raf-1 ablation. The recent demonstration of 
interaction between Raf-1 and ASK1 indicates that Raf-1 may pro-
Figure 4
Western blot analysis of Raf CKO mice. The 
phosphorylation levels of MEK1/2, ERK, p38, JNK, 
and Akt were assessed by immunoblotting with anti-
phosphospecific antibody. The filters were reprobed 
with anti-nonphosphospecific antibody. (A) Western 
blot analysis of MEK1/2 and ERK phosphorylation 
in the hearts of Raf CKO mice and CTLs after 3 
minutes of perfusion with endothelin-1 (ET-1) 
or PBS stimulation. (B) Western blot analysis of 
MEK1/2 phosphorylation in the hearts of Raf CKO 
mice and CTLs at 2, 4, and 10 weeks of age. (C) 
Western blot analysis of ERK, p38, JNK, and Akt 
phosphorylation in the hearts of Raf CKO mice and 
CTLs at 2, 3, 4, 5, 6, 7, 8, and 10 weeks of age.
Figure 5
ASK1 activity in Raf CKO mice. ASK1 activity was measured by 
immune complex assay, using His-MKK6 as a substrate. Panels repre-
sent ASK1 activation at 2, 4, and 10 weeks of age.
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mote cell survival through its protein-protein interactions, which 
are not related to Raf-1 kinase activity (7). It is possible to hypoth-
esize that Raf-1 promotes cardiomyocyte survival by antagonizing 
ASK1. Deletion of the N-terminal domain of ASK1 caused the con-
stitutive activation of kinase activity and induction of apoptosis. 
Raf-1 has been shown to bind to the N-terminal domain of ASK1 
(7). Thus, Raf-1 might promote an inactive conformation of ASK1 
through the interaction of Raf-1 with the N-terminal domain 
of ASK1. In addition, the Fas death receptor–associated protein 
Daxx has been found to activate ASK1 through interaction with 
the N-terminal portion of ASK1 and lead to apoptosis (26). It is, 
therefore, also possible that Raf-1 interferes with the binding of 
ASK1 with Daxx; another possibility is that the antagonizing func-
tion of Raf-1 against ASK1 is mediated through Akt activation. It 
has been reported that Raf-1 is associated with Akt (27), which 
phosphorylates and negatively regulates ASK1 (28). These find-
ings indicate that Raf-1 may recruit Akt to phosphorylate ASK1, 
resulting in reduced ASK1 kinase activity. However, we could not 
detect any change of Akt activation in Raf CKO mice. It has been 
reported that H-Ras interacts with ASK1 to cause the inhibition of 
both ASK1 activity and ASK1-induced apoptosis (29). We observed 
no significant difference in the protein expression level of H-Ras 
between Raf CKO and CTL hearts (data not shown); this excludes 
the possibility that altered expression levels of H-Ras in Raf CKO 
hearts could contribute to enhancement of ASK1 activity.
To summarize, Raf CKO mice exhibited cardiac dysfunction and 
dilatation with increased apoptosis. Activation of the ASK1 sig-
naling pathway seems to play an important role in apoptosis in 
Raf-1–knockout hearts.
Methods
Generation of the Raf CKO mice. The construction of c-raf-1flox/flox and ASK1-
depleted mice has been previously described in detail (6, 9). The transgenic 
mice expressing the Cre recombinase under the control of α-myosin heavy 
chain promoter (α-MHCCre mice) in C57BL/6J background were gener-
ated as previously reported (17). To confirm the cardiac-specific expression 
of the Cre recombinase in the α-MHCCre mice, they were mated with a 
transgenic mouse line carrying a reporter gene construct, which directs 
expression of the Escherichia coli lacZ gene following Cre-mediated excision 
of the loxP-flanked chloramphenicol acetyltransferase gene (30). Cross-
ing the α-MHCCre mice with the reporter mice resulted in Cre-mediated 
recombination in the heart, but not in other tissues, as determined by X-gal 
staining (data not shown). The c-raf-1flox/flox mice were mated with α-MHC-
Cre mice to obtain c-raf-1flox/flox:α-MHCCre(+) mice, which harbor cardiac 
muscle–specific Raf-1 knockout. The ASK–/– mice were in the C57BL/6J 
background and were crossed with c-raf-1flox/flox:α-MHCCre(+) mice to obtain 
double-knockout mice [c-raf-1flox/flox:α-MHCCre(+):ASK–/–].
This study was carried out under the supervision of the Animal Research 
Committee of Osaka University and in accordance with the Guidelines for 
Animal Experiments of Osaka University and the Japanese Animal Protec-
tion and Management Law (No. 25).
Echocardiography and hemodynamic analysis. Sequential murine transtho-
racic echocardiography (SONOS 5500, equipped with a 15-MHz linear 
transducer; Philips Medical Systems) was performed on anesthetized mice 
intraperitoneally injected at 5, 10, and 15 weeks with 2.5% avertin (8 μl/g), 
as previously described (31). Hemodynamic measurements were performed 
on mice intraperitoneally anesthetized with 100 mg/kg ketamine and 5 
mg/kg xylazine, as done previously (32).
Histological analysis. The heart samples were arrested in diastole and 
immediately fixed with buffered 3.7% formalin, embedded in paraffin, and 
sectioned at 3 μm thickness. H&E or Masson trichrome staining was per-
formed on serial sections.
Figure 6
Prevention of cardiac dysfunction in Raf-1/ASK1 double-knockout 
mice. (A) Photographs of hearts removed from c-raf-1flox/flox:α-MHC-
Cre(+):ASK+/+ (Raf CKO:ASK+/+) and Raf-1/ASK1 double-knockout, 
c-raf-1flox/flox:α-MHCCre(+):ASK–/– (Raf CKO:ASK–/–) mice at 10 weeks 
of age. (B) Western blot analysis of Raf-1 in the hearts of CTLs, Raf 
CKO:ASK+/+, and Raf CKO:ASK–/– mice. (C and D) Echocardiographi-
cal analysis of hearts at 10 weeks of age. (C) Transthoracic M-mode 
echocardiographic tracings. (D) FS and diastolic left ventricle internal 
dimension (LVDd) in Raf CKO:ASK+/+ mice (n = 8) and Raf CKO:ASK–/– 
mice (n = 7). The parameters in c-raf-1flox/flox:α-MHCCre(–):ASK+/+ 
(CTL:ASK+/+) mice (n = 6) and c-raf-1flox/flox:α-MHCCre(–):ASK–/– 
(CTL:ASK–/–) mice (n = 6) are also shown as reference. *P < 0.05 
versus each group. (E) Cardiac histological analysis of the Raf-1/
ASK1 double-knockout mice. Microscopic H&E-stained and Masson 
trichrome–stained sections of hearts from Raf CKO:ASK+/+ and Raf 
CKO:ASK–/– mice. (F) The phosphorylation level of JNK or p38 was 
assessed by immunoblotting with anti-phosphospecific antibody in Raf 
CKO:ASK–/– and Raf CKO:ASK+/+ hearts at 3 and 4 weeks of age. (G) 
The number of TUNEL-positive cells in Raf CKO:ASK–/– and Raf CKO:
ASK+/+ hearts at 4 and 10 weeks of age. *P < 0.05 versus Raf CKO:
ASK+/+ at the same age. Scale bar: 10 mm (A), 100 μm (E).
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Evaluation of apoptosis. To determine the quantity of cells undergoing 
nuclear fragmentation, TUNEL assay was performed on paraffin-embed-
ded heart sections using an in situ apoptosis detection kit (Takara Bio 
Inc.). The number of TUNEL-positive nuclei was counted by examination 
of the entire section with a ×40 objective. Triple staining with propidium 
iodide (Vector Laboratories Inc.), TUNEL, and anti–α-sarcomeric actin 
antibody (Sigma-Aldrich) was performed.
Western blots. Mouse cardiac homogenates were prepared as previously 
described (33). Total protein homogenates (50 μg/lane) were subjected 
to Western blot analysis using antibodies against mouse Bax (N-20), 
p38 (N-20), ERK1 (K-23), JNK1 (FL), and H-Ras (C-20) from Santa Cruz 
Biotechnology Inc.; antibodies against MEK1/2, phospho–MEK1/2, 
phospho-ERK, phospho-JNK, phospho-p38, Akt, and phospho-Akt 
from Cell Signaling Technology Inc.; and antibody against Raf-1 from 
Transduction Laboratories. Western blots were developed with the ECL 
kit, ECL Plus kit, or ECL Advance kit (Amersham Biosciences Corp.). 
Quantification of signals was performed by densitometry of scanned 
autoradiographs with the aid of Scion Image software (version 4.02; 
Scion Corp.). In some studies, mice were treated before excision with 
endothelin-1 (50 mg/kg/min, intra-arterial perfusion) for 3 minutes to 
activate MAPK.
In vitro kinase assay. The activity of ASK1 was measured by immune 
complex kinase assay as described previously (8). Immunoprecipitation 
of endogenous ASK1 was performed on 500 μg of myocardial extracts as 
reported previously (23). Immune complex kinase activity was measured 
as previously described (34).
Statistical analysis. Results are shown as mean ± SEM. Paired data were 
evaluated by Student’s t test. A 1-way ANOVA with the Bonferroni’s post 
hoc test or repeated-measures ANOVA was used for multiple comparisons. 
A value of P less than 0.05 was considered statistically significant.
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